ArticleScientific reports2026
Constructing a prognostic survival model for patients with stage II-IV epithelial ovarian cancer: a study based on the SEER database and external validation in China.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study utilized the Surveillance, Epidemiology, and End Results (SEER) database to identify clinicopathological prognostic factors and develop a prognostic nomogram for predicting 1-, 3-, and 5-year overall survival (OS) in patients with stage II-IV epithelial ovarian cancer (EOC), aiming to enhance survival prediction accuracy and inform personalized therapeutic strategies. Clinical data of patients diagnosed between 2004 and 2020 were extracted and randomly divided into training, tuning, and internal validation cohorts at a 7:2:1 ratio. Univariate and multivariate Cox regression analyses identified age, tumor differentiation grade, AJCC stage, tumor size, number of positive lymph nodes, number of lymph nodes examined, surgery, chemotherapy, sequence of systemic therapy and surgery, and time from diagnosis to treatment as independent prognostic factors for OS (all P < 0.05). A prognostic nomogram was subsequently developed and externally validated using an independent cohort of 115 EOC patients from Chengde Medical University (2014-2020). The model exhibited acceptable discriminative performance, with concordance indexes (C-index) of 0.693, 0.683, and 0.700 for the training, internal validation, and external validation cohorts, respectively. Calibration curves, receiver operating characteristic (ROC) curves, and area under the curve (AUC) values all exceeded 0.7, indicating reliable prediction of 1-, 3-, and 5-year survival rates. Kaplan-Meier curves revealed significant survival differences across risk groups, and decision curve analysis (DCA) confirmed the clinical utility of the nomogram. In conclusion, this externally validated nomogram can assist in predicting OS in patients with stage II-IV EOC, demonstrating moderate yet clinically useful performance with a C-index of 0.700. It addresses the need for personalized prognostic assessment and aids in tailoring therapeutic strategies, thereby potentially improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.